新型头孢类抗生素抑菌增效剂阿维巴坦项目介绍（精选）

动力学稳定、毒副作用微弱、耐受性强,符合临床对抗菌药物耐药菌Р方面的开发需要和合理的复方制剂。Р Р Р 参考文献: Р [1] avibactam sodium + ceftazidime,THOMSON REUTERS PHARMATM, 12-NOV-2014 Р[2] avibactam sodium + ceftaroline,THOMSON REUTERS PHARMATM, 12-NOV-2014 Р[3] aztreonam + avibactam,THOMSON REUTERS PHARMATM, 12-NOV-2014 Р[4] 新型β-内酰胺酶抑制剂——阿维巴坦的研究进展,国外医药抗生素分册,2014 年第 35 卷第 2Р 期Р[5] 抗革兰阴性细菌感染抗生素的研发新进展,药学学报,2013, 48 (7): 993−1004 Р[6] Kimberly A. Toussaint, Pharm D, Jason C. Gallagher, PharmD, β-Lactam/β-Lactamase Inhibitor Р Combinations: From Then to Now,Annals of Pharmacotherapy, DOI: 10.1177/1060028014556652 Р[7] Philippe Lagacé-Wiens, Andrew Walkty, James A Karlowsky, Ceftazidime–avibactam: an Р evidence-based review of its pharmacology and potential use in the treatment of Gram-negative Р bacterial infections, Core Evid, 2014, 9:13-25.